Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients

Environmental and Molecular Mutagenesis

Volumn 49, Issue 9, 2008, Pages 676-687

  Albertini, Mark R ^a,b,c   Macklin, Michael D ^b   Zuleger, Cindy L ^b   Newton, Michael A ^b,c   Judice, Stephen A ^d   Albertini, Richard J ^e  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d Whatman Inc   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; T LYMPHOCYTE RECEPTOR BETA CHAIN; TIOGUANINE;

ARTICLE; CELL CLONING; CELL EXPANSION; CELL FRACTIONATION; CELL MIGRATION; CLONAL VARIATION; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DNA SEQUENCE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; T LYMPHOCYTE;

CELL PROLIFERATION; CLONE CELLS; DRUG RESISTANCE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MUTATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; THIOGUANINE;

EID: 58049192775     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20417     Document Type: Article

References (40)

1. Agresti A. 2002. Categorical Data Analysis, 2nd ed. New York:Wiley Interscience. 734p.
2. Albertini MR, King DM, Newton MA, Vacek DM. 2001. In vivo mutant frequency of thioguanine-resistant T-cells in the peripheral blood and lymph nodes of melanoma patients. Mutat Res 476:83-97.
3. Albertini RJ. 2001. HPRT mutations in humans: Biomarkers for mechanistic studies. Mutat Res 489:1-16.
4. Albertini RJ, Nicklas JA, Skopek TR, Recio L, O'Neill JP. 1998. Genetic instability in human T-lymphocytes. Mutat Res 400:381-389.
5. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. 1990. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718-721.
6. Alt FW, Oltz EM, Young F, Gorman J, Taccioli G, Chen J. 1992. VDJ recombination. Immunol Today 13:306-314.
7. Ansari AA, Mayne A, Sundstrom JB, Gravanis MB, Kanter K, Sell KW, Villinger F, Siu CO, Herskowitz A. 1995. Frequency of hypoxanthine guanine phosphoribosyltransferase (HPRT-) T cells in the peripheral blood of cardiac transplant recipients. A noninvasive technique for the diagnosis of allograft rejection. Circulation 92:862-874.
8. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. 2001. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648.
9. Baner J, Baner J, Marits P, Nilsson M, Winqvist O, Landegren U. 2005. Analysis of T-cell receptor Vβ gene repertoires after immune stimulation and in malignancy by use of padlock probes and microarrays. Clin Chem 51:768-775.
10. Butler JE, Wertz N, Sun J, Sacco RE. 2005. Comparison of the expressed porcine Vβ and Jβ repertoire of thymocytes and peripheral T cells. Immunology 114:184-193.
11. Dawisha SM, Gmelig-Meyling F, Steinberg AD. 1994. Assessment of clinical parameters associated with increased frequency of mutant T cells in patients with systemic lupus erythematosus. Arthritis Rheum 37:270-277.
12. Degauque N, Schadendorf D, Brouard S, Guillet M, Sebille F, Hohn H, Pallier A, Ruiz C, Dupont A, Chapin S, Hofmann U, Maeurer M, Soulillou JP. 2004. Blood T-cell Vβ transcriptome in melanoma patients. Int J Cancer 110:721-729.
13. Falta MT, Magin GK, Allegretta M, Steinman L, Atkinson MA, Brostoff SW, Albertini RJ. 1999. Selection of HPRT mutant T cells as surrogates for dividing cells reveals a restricted T cell receptor BV repertoire in insulin-dependent diabetesmellitus. Clin Immunol 90:340-351.
14. Finette BA, Homans AC, Albertini RJ. 2000. Emergence of genetic instability in children treated for leukemia. Science 288:514-517.
15. Gmelig-Meyling F, Dawisha S, Steinberg AD. 1992. Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus. J Exp Med 175:297-300.
16. Holyst MM, Hill DL, Sharp GC, Hoffman RW. 1994. Increased frequency of mutations in the HPRT gene of T cells isolated from patients with anti-U1-70kD-autoantibody-positive connective tissue disease. Int Arch Allergy Immunol 105:234-237.
17. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347-352.
18. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968.
19. Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon YL, Slingluff CL, Jr, Kirkwood JM, Storkus WJ. 2001. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD41T cells. Br J Cancer 85:1738-1745.
20. Killian MS, Matud J, Detels R, Giorgi JV, Jamieson BD. 2002. MaGiK method of T-cell receptor repertoire analysis. Clin Diagn Lab Immunol 9:858-863.
21. Lefranc MP. 2004. IMGT-ONTOLOGY and IMGT databases, tools and Web resources for immunogenetics and immunoinformatics. Mol Immunol 40:647-660.
22. Lefranc MP, Lefranc G. 2001. The T Cell Receptor FactsBook. London, UK:Academic Press. 398p.
23. Lefranc MP, Giudicelli V, Kaas Q, Duprat E, Jabado-Michaloud J, Scaviner D, Ginestoux C, Clement O, Chaume D, Lefranc G. 2005. IMGT, the international ImMunoGeneTics information system®. Nucl Acids Res 33:D593-D597.
24. Lewis SM. 1994. The mechanism of V(D)J joining: Lessons from molecular, immunological, and comparative analyses. Adv Immunol 56:27-150.
25. Meidenbauer N, Zippelius A, Pittet MJ, Laumer M, Vogl S, Heymann J, Rehli M, Seliger B, Schwarz S, Le Gal FA, Dietrich PY, Andreesen R, Romero P, Mackensen A. 2004. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 64:6319-6326.
26. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT. 1989. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961-1976.
27. Nuovo GJ, Nuovo GJ, Morrison C, Porcu P, Caligiuri MA, Suster S. 2001. In situ determination of T-cell receptor beta expression patterns. J Histochem Cytochem 49:139-145.
28. O'Neill JP, McGinniss MJ, Berman JK, Sullivan LM, Nicklas JA, Albertini RJ. 1987. Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine-resistant mutant frequency in humans. Mutagen 2:87-94.
29. O'Neill JP, Nicklas JA, Hunter TC, Batson OB, Allegretta M, Falta MT, Branda RF, Albertini RJ. 1994. The effect of T-lymphocyte 'clonality' on the calculated hprt mutation frequency occurring in vivo in humans. Mutat Res 313:215-225.
30. Pardoll DM. 2002. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2:227-238.
31. Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, Parmiani G, Berd D. 1997. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest 99:710-717.
32. Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Lienard D, Cerottini JC, Romero P, Rufer N. 2006. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: Spontaneous priming and efficient boosting by vaccination. J Immunol 177:1338-1348.
33. The international ImMunoGeneTics information system (IMGT) (http://imgt.cines.fr).
34. Tonegawa S. 1983. Somatic generation of antibody diversity. Nature 302:575-581.
35. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA. 1994. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461-9465.
36. Van den Berg LH, Mollee I, Wokke JH, Logtenberg T. 1995. Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: Further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 58:37-42.
37. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647.
38. Willhauck M, Mohler T, Scheibenbogen C, Pawlita M, Brossart P, Schmier JW, Keilholz U. 1996. T-cell receptor β variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. Clin Cancer Res 2:767-772.
39. Willhauck M, Scheibenbogen C, Pawlita M, Mohler T, Thiel E, Keilholz U. 2003. Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. Cancer Res 63:3483-3485.
40. Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. 2002. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res 62:213-218.